Cure My Disease

Don't miss your cure!

 Log in / Sign up

Antiparasitic drug tested as new weapon against ulcerative colitis

NCT ID NCT07820046

Disease control Sponsor: Tanta University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time

Summary

Researchers are testing whether nitazoxanide, an antiparasitic drug with anti-inflammatory properties, can help people with mild-to-moderate ulcerative colitis when added to their usual treatment. The trial enrolls adults aged 18 to 65 with active disease and stable therapy. Over 12 weeks, participants receive either nitazoxanide or a placebo, and researchers track changes in a standard disease activity score.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nitazoxanide, an antiparasitic drug with anti-inflammatory effects
What this could lead to
If it works, nitazoxanide could offer an inexpensive add-on option for people whose ulcerative colitis does not fully respond to standard therapy.
What could go wrong
The trial is small and early, and nitazoxanide has not been proven to help ulcerative colitis in people. It may cause side effects or fail to improve symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 44 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Age 18-65 years * Confirmed ulcerative colitis ≥ 6 months * Mild-to-moderate active disease (Mayo score 3-10) * Stable UC therapy ≥ 8 weeks before enrollment Exclusion Criteria * Severe/fulminant UC requiring hospitalization or surgery * Active intestinal infection (e.g., C. difficile) * Antibiotics/probiotics/investigational drugs within 4 weeks * Recent biologic initiation or dose change * Severe hepatic, renal, cardiovascular disease, or malignancy * Pregnancy or lactation * Known hypersensitivity to nitazoxanide

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ulcerative colitis (UC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ulcerative colitis (UC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.